Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Clinical trial NCT02989844 · COMPLETED

Trial details

NCT number: NCT02989844
Sponsor: Masonic Cancer Center, University of Minnesota
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome (MDS)

Start date: 2017-04-12
Primary completion: 2022-03-19
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.